Stockreport

Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – Less frequent administration of HEMLIBRA demonstrated clinically meaningful bleed control – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- G [Read more]